Special Emphasis Panel for Immune Oncology R21 – CII (81)
This SEP reviews R21 applications in immuno-oncology areas, including identification of biomarkers in response to immunotherapies. The focus is the development of antibody therapies including novel immune checkpoint inhibitors that can overcome resistance mechanisms, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates. Additionally, computational approaches for new target discovery and the use of novel technologies for cancer immunotherapy will be assigned to this SEP. It encompasses scientific disciplines covered by the Translational Immune Oncology (TIO) and Therapeutic Immune regulation (TIR) scientific review groups.
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Antibody and antibody-based constructs, including antibody-drug conjugates (ADCs), to deliver cancer therapy or to activate anti-tumor immune responses
- Interactions between tumor cells and immune cells
- Predictive biomarkers of a patient or tumor’s clinical response to immunotherapies
- Tumor metabolic reprogramming in cancer immunology and immunotherapy
- Computational approaches and novel technologies for cancer immunotherapy
